Introduction of Mechanical Sphincter Augmentation for Gastroesophageal Reflux Disease into Practice: Early Clinical Outcomes and Keys to Successful Adoption
Authors:
- 1 April 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 218 (4) , 776-781
Abstract
A new device for mechanical sphincter augmentation (MSA) of the lower esophageal sphincter was approved by the FDA on March 22, 2012. We report early experience with MSA, specifically addressing postoperative management. Between October 1, 2011 and June 1, 2013, 150 patients were evaluated for MSA. Of these, 66 patients underwent device implantation; the first implant was April 10, 2012. All patients had objectively confirmed gastroesophageal reflux disease (GERD) with pH testing, acceptable esophageal motility, and no significant hiatal hernia (>3 cm). All patients experienced clinical improvement on antisecretory medication, but incomplete symptom control or medication intolerance. All patients were successfully implanted without intra- or perioperative complications. Average length of hospital stay was 0.7 days. At an average follow-up of 5.8 months (range 1 to 18.6 months), 92% of patients are satisfied or neutral with their GERD condition, and 83% are proton pump inhibitor free. The GERD-Health-Related Quality of Life (HRQL) scores are similar to those of patients without GERD. There were no device ulcers or erosions and no devices explanted. Thirteen patients underwent additional testing for dysphagia or persistent symptoms. Calls with questions and nursing involvement in the first 6 months postoperatively were 3 times what is typical for fundoplication patients. Dysphagia and regurgitation were the most common concerns. All these symptoms were improving over time. Single-center early results are promising and parallel those from a multicenter trial. There is significant interest in MSA, with referrals and direct patient appointments specifically for MSA. Outcomes improve over time after implantation. The surgeon learning curve is different than with the Nissen, both in operative technique and postoperative management. This is a promising new offering for patients with GERD, and surgeons will need to learn how to integrate this into their practices.Keywords
This publication has 11 references indexed in Scilit:
- One Hundred Consecutive Patients Treated with Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease: 6 Years of Clinical Experience from a Single CenterJournal of the American College of Surgeons, 2013
- LINX® Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to refluxTherapeutic Advances in Gastroenterology, 2013
- Esophageal Sphincter Device for Gastroesophageal Reflux DiseaseNew England Journal of Medicine, 2013
- LINX™Reflux Management System: magnetic sphincter augmentation in the treatment of gastroesophageal reflux diseaseExpert Review of Gastroenterology & Hepatology, 2012
- The LINX® reflux management system: confirmed safety and efficacy now at 4 yearsSurgical Endoscopy, 2012
- Laparoscopic Sphincter Augmentation Device Eliminates Reflux Symptoms and Normalizes Esophageal Acid ExposureAnnals of Surgery, 2010
- Surgical Therapy for Gastroesophageal Reflux Disease: Indications, Evaluation, and ProceduresGastrointestinal Endoscopy Clinics of North America, 2009
- Magnetic Augmentation of the Lower Esophageal Sphincter: Results of a Feasibility Clinical TrialJournal of Gastrointestinal Surgery, 2008
- Use of a magnetic sphincter for the treatment of GERD: a feasibility studyGastrointestinal Endoscopy, 2008
- The development of the GERD-HRQL symptom severity instrumentDiseases of the Esophagus, 2007